“We set up everything needed for a massive clinical study, one that usually takes months, in just nine weeks”
How Wemedoo’s agile approach is redefining speed and efficiency for global CROs.
Speed, efficiency, and collaboration are at the heart of modern clinical research — and Wemedoo is leading that transformation. Founded by Dr. med. Nikola Cihoric, Wemedoo was born out of a desire to break down the persistent barriers slowing down clinical trials: outdated workflows, siloed systems, and overwhelming paperwork. With over 20 years of experience in medicine and research, Dr. Cihoric saw firsthand how these obstacles delayed patient access to life-saving therapies. Determined to make a difference, he developed oomnia, an innovative e-clinical solution designed to unify researchers, clinicians, and industry partners in real-time collaboration. Wemedoo’s agile approach isn’t just theoretical—it’s proven. In a recent large-scale clinical trial, the company helped a client become patient-ready in just nine weeks, a timeline nearly unheard of in the industry. Through advanced technologies like AI, regulatory adaptability, and a global partnership with the ACROSS Global Alliance, Wemedoo is redefining how clinical data is managed, shared, and analyzed across borders. More than a technology provider, Wemedoo champions a patient-centered vision, ensuring that innovation serves the people who need it most.
Interview with Dr. med. Nikola Cihoric, founder of Wemedoo and creator of the e-clinical solution oomnia
Can you describe your entrepreneurial journey and the motivation behind starting your business?
I have spent over two decades in medicine and clinical research, and during that time, I kept running into the same barriers: siloed systems, complicated workflows, and endless paperwork. These are not just annoying obstacles; they slow down the process of getting new treatments to patients who need them. It became clear to me that we had to rethink the way clinical trials are run.
So, I founded Wemedoo with the idea of building something that brings people together rather than adding more steps to their day. Our goal was not just to create another piece of software, it was to develop an ecosystem where clinicians, researchers, and industry players can collaborate in real-time. We wanted to cut through outdated workflows and make sure that technology genuinely serves the people driving innovation.
At the end of the day, it is about patients and the researchers who work tirelessly on their behalf. By shortening trial timelines and reducing administrative burdens, we are hoping to accelerate access to new therapies. That is why we built oomnia – it is designed to empower those at the forefront of medical progress.
How do you stay ahead of technological advancements in your industry, and how has this impacted your business model?
We make it a priority to stay current on every development in health tech, AI, and shifting regulations because this industry changes so quickly. In practice, that means we actively follow research publications, engage with regulators, and attend relevant conferences to see where things are headed. By doing this, we can continuously adapt our roadmap and ensure our platform can support emerging technologies.
This forward-looking approach has fundamentally shaped our business model: we have built oomnia to be a platform rather than a closed product. So whenever new tools or regulations come along, we can integrate them smoothly without having to overhaul our entire system. It is an investment in flexibility that lets us stay one step ahead and keeps our focus on innovation rather than just maintenance.
What role does artificial intelligence play in your current operations or future plans?
Right now, AI is already helping us refine data analysis, automate regulatory tasks, and uphold strong protocol compliance. These applications have made our processes smoother and more efficient, and we see even bigger opportunities ahead, like using AI to predict outcomes, harmonize diverse datasets, and enable real-time decision-making in clinical trials. By doing so, we hope to catch problems earlier, make better use of resources, and bring therapies to patients faster.
However, the real magic of AI in healthcare happens only when data is both high-quality and truly interoperable. We have focused on building that foundation from day one, ensuring that clinical data can be exchanged seamlessly across various platforms and stakeholders. As a result, major tech partners view us as a safeguard for clinical data, because we add the vital clinical perspective AI alone cannot replicate. That blend of medical depth and advanced technical capabilities is what makes our solutions stand out.
Can you share a significant challenge you have faced in your business and how you overcame it?
One of the toughest hurdles we faced was persuading big pharma and biotech companies to embrace a more modern digital ecosystem. Many were understandably cautious about changing long-standing practices, and compliance concerns made them even more hesitant. We realized early on that we could not just promise improvements, but we had to show them in real, measurable ways.
We recognize that the clinical trial industry is undergoing a major transformation. Rather than just meeting regulatory standards, we positioned oomnia as the bridge to this new era, one that enhances efficiency, ensures compliance, and accelerates trial outcomes. Through strategic demos, pilot projects, and transparent discussions, we demonstrated how our system not only adapts to these changes but also empowers organizations to stay ahead. Trust was not built overnight, but by proving, through data and real-world success, that AI-driven innovation can be both compliant and transformative, we helped the industry embrace a smarter, more agile future.
How do you approach strategic planning and decision-making in your organization?
Our strategic planning starts with data. We continuously track performance metrics and gather customer feedback to guide our next moves. At the same time, we’re structured in a way that lets us pivot quickly whenever regulations shift, or new opportunities arise. This adaptability is deeply ingrained in our culture.
In clinical trials complex protocols and regulatory hurdles can delay progress for months, speed without compromising quality is a game-changer.
A prime example of this was when we supported a client in setting up a large-scale clinical trial with over 5,000 questions. Despite the complexity, we had them ready to enroll their first patient in just nine weeks. Meanwhile, a global CRO, handling another arm of the same study was still months away from activation. Everyone in our industry knows how big that achievement is; launching a trial of this scale in such a short time is nearly unheard of. This showcased our commitment to nurturing a mindset that values speed, collaboration, and the willingness to adapt when the situation calls for it.
What is your approach to leadership and fostering a positive company culture?
At Wemedoo, leadership has never been about a single person at the top making central decisions. It is about creating an environment where transparency, openness, and learning are woven into our day-to-day operations. We are a diverse team, bringing backgrounds in software, healthcare, data science, and more. We are all united by a desire to reshape clinical research for the better.
Just like in a hospital setting, where physicians and nurses from different medical disciplines collaborate to find the best outcome for the patient, we value every perspective and idea. This collaborative spirit means challenges are not roadblocks, they are opportunities to learn and improve.
How do you ensure your business remains adaptable and responsive to market changes?
Our commitment to adaptability runs deep because clinical research is not static. It is dynamic, like medicine itself. We aim to unite diverse data, systems, and teams so that real-time collaboration becomes the norm rather than the exception. In building oomnia, we focused on flexibility: the system can be quickly tailored to different workflows, ensuring that clinicians and researchers are not forced to adapt to the software. The software adapts to them.
We have also taken great care to meet local and global regulatory requirements without sacrificing this adaptability. Where traditional solutions may address isolated issues or keep their users in proprietary ecosystems, we have chosen a different path, one that is more global and inclusive. We do not design for a single stakeholder or region. Instead, we create an environment that benefits patients and healthcare professionals everywhere, encouraging open collaboration and broader knowledge-sharing.
Can you discuss a recent innovation or project that has been particularly successful for your company?
Our partnership with the ACROSS Global Alliance is one of our most meaningful initiatives to date. ACROSS unites 16 Clinical Research Organizations operating across 60+ countries, and we have been awarded to provide the central infrastructure through our eClinical software solution, oomnia. Essentially, we are bringing everyone onto one unified system, where data can be shared in real-time and operational workflows are streamlined across borders.
The impact on real-world data collection is especially noteworthy. Local CROs maintain their unique expertise and regional adaptability, but now they contribute to a shared data environment that can be easily harmonized and analyzed. This collaboration goes beyond just quicker trial timelines, it is reshaping how global research is conducted, making RWD a more robust source for regulatory decisions and paving the way for AI applications in the future.
What are your long-term goals for your business, and how are you working towards achieving them?
Our long-term goal at Wemedoo is to build a comprehensive digital environment for clinical research that reimagines how data is handled and shared. We want to establish new benchmarks for data integrity, interoperability, and speed – improvements that can reshape the entire research process, not just specific parts of it.
Clinical data is becoming more diverse every day, whether it is imaging, pathology, genomic data, or AI-generated insights. Traditional platforms were not designed to handle this complexity, which is why we developed oomnia to break down these barriers. By connecting experts, institutions, and researchers worldwide in real-time, we are setting the stage for new, globally scalable models of collaboration.
To bring this vision to life, we are working on partnerships that include every stakeholder: patients, providers, CROs, insurers, and more. We want oomnia to adapt seamlessly to local and global needs alike, ensuring clinical research can be conducted smarter, faster, and with greater impact. Ultimately, it is about creating a unified ecosystem that moves the entire field forward.
What advice would you give to emerging entrepreneurs in your industry?
My biggest tip for anyone starting is to keep your passion at the forefront. Healthcare is personal by nature. Real people rely on these technologies and treatments. If you are only in it for the business angle, it is easy to lose momentum when the going gets tough, and it will get tough.
Next, dare to think differently. Healthcare is full of legacy systems and practices that might not serve us well in the modern age. Bold ideas often spark the most transformative changes, but you will need resilience to carry them through.
Finally, understand that collaboration beats competition in healthcare. Innovations are more powerful when they are designed to integrate with existing workflows, respect the perspectives of all stakeholders, and make the industry more open and interoperable. Make it your goal to break down walls, share knowledge, and unite diverse expertise. That is how genuine progress in medicine is achieved.
